KR KRSNAA
Krsnaa Diagnostics Q3 2025
KRKRSNAA

Krsnaa Diagnostics Q3 FY25 results (Oct–Dec 2024) and concall

Healthcare · Concall AI · Call held 13 Feb 2025

Management summary

  • Krsnaa Diagnostics reported strong 9-month FY25 results with 17% revenue growth and 39% EBITDA growth, driven by operational efficiencies.
  • Q3 saw some revenue moderation due to seasonal factors, project delays, and receivable issues in certain states.
  • The company remains net debt-free and is aggressively expanding its retail footprint and operationalizing new centers, aiming to meet its full-year guidance.

Source: Inve concall analysis and management guidance record.

Highlights

  • Krsnaa Diagnostics achieved an impressive 17% year-on-year revenue growth, reaching INR531.1 crores in the first 9 months of FY25.

  • EBITDA surged 39% year-on-year to INR141.6 crores with margins improving to 27% for the first 9 months of FY25.

  • The company achieved a remarkable profit of INR56.9 crores in the 9 months ending FY25, equalling the full-year profit of the previous year, demonstrating strong operational efficiency.

  • Net profit for Q3 FY25 stood at INR19.4 crores, registering a 50% growth year-on-year.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25
Revenue9
EBITDA48
Net profit22
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • FY25 Revenue Growth Revenue · FY25 · High confidence 25%

Receivables

  • HP Karnataka Receivable Days Receivables · by year-end · High confidence 90 days

    From 120 days today

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
FY25 Revenue Growth Guidance vs. 9M Performance Direct
Had these aberrations not happened or the delays would have happened, we would have been on the track to maintain the guidance that we've given. And we believe with certain actions, strategic initiatives we've taken, we are hopeful to achieve this by Q4 as well.

Analyst questioned the feasibility of achieving 25% FY25 revenue growth guidance given 17% in 9M and Q3 challenges, prompting management to reaffirm commitment with strategic initiatives.

Asked by Ranvir Singh

Receivables from Himachal Pradesh and Karnataka Partial
INR30 crores of Himachal Pradesh has already received, as I mentioned already on the call, Neha. And certain, another payment from Himachal, which is already approved at the last stage, where we are expecting by end of February or first week of March. ... Karnataka, the payments

Analyst pressed for specific numbers on pending receivables, and management provided partial recovery details and timelines for the rest, indicating ongoing challenges but expected resolution.

Asked by Neha Kharodia

Unlock risks & concerns, Q4 FY25 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 7 risks, concerns & management red flags
  • 5 watchlist triggers for Q4 FY25
  • +5 more guidance targets & verbatim management quotes
  • +5 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image